Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$19.64
$19.70
$16.65
$31.26
$865.98M0.89587,540 shs315,754 shs
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$225.77
-0.1%
$209.31
$159.33
$228.57
$73.31B1.292.63 million shs1.67 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-2.29%-6.65%+6.45%-3.96%-16.71%
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
+1.30%+0.30%+10.96%+19.64%+36.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$19.64
$19.70
$16.65
$31.26
$865.98M0.89587,540 shs315,754 shs
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$225.77
-0.1%
$209.31
$159.33
$228.57
$73.31B1.292.63 million shs1.67 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-2.29%-6.65%+6.45%-3.96%-16.71%
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
+1.30%+0.30%+10.96%+19.64%+36.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1.63
Reduce$22.0012.02% Upside
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
2.47
Hold$211.47-6.33% Downside

Current Analyst Ratings Breakdown

Latest AMPH and SPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
DowngradeOutperformPeer Perform
6/29/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
DowngradeBuy (A-)Buy (B)
6/29/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Reiterated RatingNeutralUnderperform$25.00 ➝ $20.00
6/29/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
Boost Price TargetBuy$225.00 ➝ $236.00
6/26/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
UpgradeStrong-Buy
6/25/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
Boost Price TargetEqual Weight$212.00 ➝ $213.00
6/23/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
Boost Price TargetHold$196.00 ➝ $215.00
6/22/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
DowngradeHoldStrong Sell
6/18/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
Set Price Target$220.00
6/18/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
Boost Price TargetSector Perform$206.00 ➝ $220.00
6/15/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
UpgradeBuy (B+)Buy (A-)
(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$719.89M1.20$4.25 per share4.62$17.17 per share1.14
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$6.36B11.50$17.99 per share12.55$18.75 per share12.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$98.09M$1.6611.836.703.8611.00%15.12%7.14%8/6/2026 (Estimated)
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$4.63B$14.3915.6916.544.0970.60%104.54%12.76%8/10/2026 (Estimated)

Latest AMPH and SPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$1.46$1.48+$0.02$1.48$1.54 billion$1.76 billion
5/7/2026Q1 2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.70$0.42-$0.28$0.14$173.46 million$171.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
$9.003.99%+7.34%62.54%4 Years

Latest AMPH and SPG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2026
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
quarterly$2.254.25%6/9/20266/9/20266/30/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.79
3.85
2.82
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
4.68
0.84
0.84

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
93.01%

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
29.60%
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
8.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,97644.09 million31.04 millionOptionable
Simon Property Group, Inc. stock logo
SPG
Simon Property Group
3,600324.29 million295.98 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$19.64 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$19.65 +0.01 (+0.05%)
As of 07/2/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Simon Property Group stock logo

Simon Property Group NYSE:SPG

$225.77 -0.29 (-0.13%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$225.98 +0.21 (+0.09%)
As of 07/2/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Simon Property Group, Inc. (NYSE:SPG) is a self-administered and self-managed real estate investment trust (REIT). Simon Property Group, L.P., or the Operating Partnership, is our majority-owned partnership subsidiary that owns all of our real estate properties and other assets. In this package, the terms Simon, we, our, or the Company refer to Simon Property Group, Inc., the Operating Partnership, and its subsidiaries. We own, develop and manage premier shopping, dining, entertainment and mixed-use destinations, which consist primarily of malls, Premium Outlets, The Mills, and International Properties. At June 30, 2024, we owned or had an interest in 230 properties comprising 183 million square feet in North America, Asia and Europe. We also owned an 84% interest in The Taubman Realty Group, or TRG, which owns 22 regional, super-regional, and outlet malls in the U.S. and Asia. Additionally, at June 30, 2024, we had a 22.4% ownership interest in Klépierre, a publicly traded, Paris-based real estate company, which owns shopping centers in 14 European countries.